Pharmaceutical firm Lupin announced that it has received tentative approval from the US health regulator to market its generic version of Dolutegravir and Rilpivirine tablets used in treatment of HIV infection, in an exchange filing.
The tentative approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg, Lupin said in the filing.
The Dolutegravir and Rilpivirine tablets, 50 mg/25 mg had estimated annual sales of USD 666 million in the US, the company said citing IQVIA MAT September 2022 data.
Maharashtra Grants Full Legal Validity To Digitally Signed Land Records
Maharashtra Election Commissioner Orders Strict Checks For Duplicate Voters In Municipal Poll Lists
'Didn't Start It, Will Finish When Our Goals Are Met': Putin On Russia–Ukraine War
VIDEO: PM Modi Welcomes Russian President Vladimir Putin, Shares Glimpses Of Car Ride To Lok Kalyan Marg Residence
